{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:52:35Z","timestamp":1773964355859,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.hoc.2025.12.009","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:25:40Z","timestamp":1771331140000},"page":"213-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Classic Hodgkin Lymphoma in the Older Adult"],"prefix":"10.1016","volume":"40","author":[{"given":"Carrie","family":"Sha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah C.","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2025.12.009_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.009_bib2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.009_bib3","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.1998.16.12.3810","article-title":"BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP\/ABVD in patients with advanced-stage Hodgkin\u2019s lymphoma: interim report from a trial of the German Hodgkin\u2019s Lymphoma Study Group","volume":"16","author":"Diehl","year":"1998","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2025.12.009_bib4","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.hoc.2025.12.009_bib5","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2025.12.009_bib6","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","article-title":"Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study","volume":"119","author":"Proctor","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.009_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.009_bib10","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged >\/=60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"issue":"30","key":"10.1016\/j.hoc.2025.12.009_bib11","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II Study of sequential Brentuximab Vedotin and Doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10450","key":"10.1016\/j.hoc.2025.12.009_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.hoc.2025.12.009_bib21","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO-25-00439","volume":"43","author":"Ferdinandus","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.009_bib24","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.2022019536","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy","volume":"143","author":"Friedberg","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2025.12.009_bib12","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1200\/JCO-24-01278","article-title":"Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with hodgkin Lymphoma","volume":"43","author":"Torka","year":"2025","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2025.12.009_bib16","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera Alex","year":"2024","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.hoc.2025.12.009_bib17","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO-25-00204","article-title":"Nivolumab-AVD versus Brentuximab Vedotin-AVD in older patients with advanced-stage classic hodgkin lymphoma enrolled on S1826","volume":"43","author":"Rutherford","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.009_bib8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.009_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with Brentuximab vedotin in stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.hoc.2025.12.009_bib13","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2025.12.009_bib14","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended Follow-Up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.009_bib15","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2025.12.009_bib18","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1182\/blood-2004-09-3759","article-title":"Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study","volume":"106","author":"Jarrett","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.009_bib19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-Cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2025.12.009_bib23","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2025.12.009_bib25","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving Systemic Cancer Therapy: ASCO Guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2025.12.009_bib26","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/bloodadvances.2021004645","article-title":"Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma","volume":"5","author":"Orellana-Noia","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.009_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s44313-025-00084-4","article-title":"Treatment of older patients with Hodgkin lymphoma","volume":"60","author":"Park","year":"2025","journal-title":"Blood Res"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.009_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson comorbidity index: a critical review of clinimetric properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"issue":"22","key":"10.1016\/j.hoc.2025.12.009_bib29","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1182\/blood.V128.22.2405.2405","article-title":"The utility of the charlson comorbidity index in predicting use of treatment and survival in older lymphoma patients","volume":"128","author":"Shah","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.009_bib30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0165-1781(92)90005-N","article-title":"Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale","volume":"41","author":"Miller","year":"1992","journal-title":"Psychiatry Res"},{"issue":"11","key":"10.1016\/j.hoc.2025.12.009_bib31","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large B-Cell lymphoma: the prospective elderly project of the Fondazione Italiana linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2025.12.009_bib32","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/bloodadvances.2021004777","article-title":"A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL","volume":"5","author":"Isaksen","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.009_bib33","first-page":"2356","article-title":"A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma","volume":"110","author":"Lia","year":"2025","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.hoc.2025.12.009_bib35","first-page":"2353","article-title":"Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy","volume":"62","author":"Nowak","year":"2002","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.009_bib36","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/ijc.25756","article-title":"Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells","volume":"129","author":"Rettig","year":"2011","journal-title":"Int J Cancer"},{"issue":"28","key":"10.1016\/j.hoc.2025.12.009_bib37","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.009_bib38","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/bjh.19178","article-title":"Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma","volume":"204","author":"Stuver","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2025.12.009_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.70093_21","article-title":"Prognostic value of circulating tumor DNA in patients with advanced stage classic hodgkin lymphoma treated on SWOG S1826","volume":"43","author":"Paczkowska","year":"2025","journal-title":"Hematol Oncol"},{"issue":"7996","key":"10.1016\/j.hoc.2025.12.009_bib40","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"issue":"35","key":"10.1016\/j.hoc.2025.12.009_bib41","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin Lymphoma","volume":"42","author":"Heger","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825001509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825001509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:25:51Z","timestamp":1773955551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825001509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0889858825001509"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.12.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Classic Hodgkin Lymphoma in the Older Adult","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}